✦ LIBER ✦

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

✍ Scribed by Elizabeth A. Mittendorf; Guy T. Clifton; Jarrod P. Holmes; Kevin S. Clive; Ritesh Patil; Linda C. Benavides; Jeremy D. Gates; Alan K. Sears; Alexander Stojadinovic; Sathibalan Ponniah; George E. Peoples

Book ID: 112066913
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 1016 KB
Volume: 118
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.26574

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimal dose and schedule of an HER-2/ne

Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

✍ Jarrod P. Holmes; Jeremy D. Gates; Linda C. Benavides; Matthew T. Hueman; Mark G 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

Assessment of immunologic response and r

Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neupeptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

✍ Asna Amin; Linda C. Benavides; Jarrod P. Holmes; Jeremy D. Gates; Mark G. Carmic 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 486 KB

Use of booster inoculations to sustain t

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02

✍ Jarrod P. Holmes; Guy T. Clifton; Ritesh Patil; Linda C. Benavides; Jeremy D. Ga 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 361 KB

Results of the first phase 1 clinical tr

Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients : United States Military Cancer Institute Clinical Trials Group Study I-04

✍ Mark G. Carmichael; Linda C. Benavides; Jarrod P. Holmes; Jeremy D. Gates; Eliza 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Clinical and Immunologic Responses of HL

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

Final report of the phase I/II clinical

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

✍ Mittendorf, E. A.; Clifton, G. T.; Holmes, J. P.; Schneble, E.; van Echo, D.; Po 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 277 KB